All In Biotech

Drug Trial Radar · NCT00700856

Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial

Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.

Last checked: Nov 19, 2026Latest source record: Aug 27, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,371 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,371

Planned (sponsor's estimate)

Start

Sep 2008

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Italian Society of DiabetologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Associazione Medici Diabetologi (AMD); Associazione Nazionale Medici Cardiologi Ospedalieri
First posted
Jun 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: In patients with type 2 diabetes inadequately controlled with metformin, two main therapeutic options are equally plausible: add-on a sulfonylurea (SU) or a thiazolidinedione (TZD). Since the two classes of drugs clearly differ in terms of mechanisms of action, side effects, economic costs and cardiovascular risk factors profile, a direct comparison of the two therapeutic strategies would be most appropriate. Aims: 1) To evaluate the effects of add-on pioglitazone as compared with add-on a SU on the incidence of cardiovascular events in type 2 diabetic patients inadequately controlled with metformin; 2) To compare the two treatments in terms of glycemic control, safety, and economic costs. Methods: multicentre, randomised, open label, parallel group trial of 48 months duration. Eligible participants (type 2 diabetic males and females, aged 50-75 years, BMI 20-45 Kg/m2, in treatment for the last two months with metformin 2 gr/die in monotherapy and with HbA1c \> =7.0% and \<= 9.0%) will be randomized to add-on: a SU - glibenclamide (5-15 mg/die), gliclazide (30-120 mg/die), glimepiride (2-6 mg/die), chosen according to local practice - or pioglitazone (15-45 mg/die). A HbA1c value \> 8.0 % on two consecutive occasions will lead to addition of insulin to ongoing oral therapy. Primary efficacy outcome: a composite endpoint of all-cause mortality, non fatal MI (including silent MI), non fatal stroke, and unplanned coronary revascularization. Secondary outcomes. Principal secondary outcome: a composite ischemic endpoint of sudden death, fatal and non fatal acute MI (including silent MI), fatal and non fatal stroke, major amputations (above ankle), endovascular or surgical intervention on the coronary, leg or carotid arteries. Other secondary outcomes \- a composite cardiovascular end point including the primary end point plus hospitalization for heart failure, endovascular or surgical intervention on the coronary, leg or carotid arteries, silent MI, angina - by WHO criteria and confirmed by a new electrocardiogram abnormality - intermittent claudication with an ankle/brachial index lower than 090; events of heart failure; a microvascular endpoint including: plasma creatinine increase of 2 times above the baseline value or creatinine clearance reduction of 20ml/min/1. 73m2 or development of overt nephropathy (dialysis or plasma creatinine \>3,3 mg/dl) or macroalbuminuria; glycemic control (changes from baseline in HBA1c, time to failure of glycemic control, i.e., HBA1c \>8.0% on two consecutive occasions three months apart); major CV risk factors (lipids, blood pressure, microalbuminuria, inflammation markers, waist circumference); safety and side effects; direct and indirect costs. Data regarding CV endpoints, safety, tolerability, and study conduct will be monitored and analyzed by an independent committee, and will be not available to the study investigators until the closing of data collection. Efficacy end points will be analyzed on an intention-to-treat basis.

Conditions

  • Type 2 Diabetes Mellitus
  • Cardiovascular Disease

Interventions

  • add-on pioglitazoneDrug

    participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)

  • add-on sulphonylureaDrug

    participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularizationTime frame: 48 months

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Inrca - Irccs

    Ancona, Italy

  • San Donato Hospital

    Arezzo, Italy

  • University of Bari

    Bari, Italy

  • Ospedali Riuniti di Bergamo

    Bergamo, Italy

  • Policlinico S. Orsola Malpigli

    Bologna, Italy

  • Presidio Ospedaliero A.S.RE.Molise

    Campobasso, Italy

  • "Garibaldi di Nesima" Hospital

    Catania, Italy

  • "Mater Domini" University

    Catanzaro, Italy

  • M. Bufalini Hospital

    Cesena, Italy

  • ASP

    Cosenza, Italy

  • Arcispedale "S.Anna"

    Ferrara, Italy

  • University of Ferrara

    Ferrara, Italy

  • University of Florence

    Florence, Italy

  • Ospedali Riuniti

    Foggia, Italy

  • University of Genova

    Genova, Italy

  • San Salvatore Hospital

    L’Aquila, Italy

  • ASL Latina

    Latina, Italy

  • Santa Maria Goretti Hospital

    Latina, Italy

  • "Cittadella della Salute" Hospital

    Lecce, Italy

  • ASL 6

    Livorno, Italy

  • Hospital of Massa

    Massa Carrara, Italy

  • Matera Hospital

    Matera, Italy

  • "Ospedali Riuniti Papardo-Piemonte" Hospital

    Messina, Italy

  • University of Messina

    Messina, Italy

  • Istituto Scientifico San Raffaele

    Milan, Italy

  • Niguarda Cà Grande Hospital

    Milan, Italy

  • "Federico II" University

    Naples, Italy

  • Second University

    Naples, Italy

  • Complesso Sociosanitario dei Colli

    Padua, Italy

  • University of Padua

    Padua, Italy

  • University of Palermo

    Palermo, Italy

  • University of Parma

    Parma, Italy

  • University of Perugia

    Perugia, Italy

  • Civil Hospital

    Pescara, Italy

  • Ospedale Gugliemo da Saliceto

    Piacenza, Italy

  • University of Pisa

    Pisa, Italy

  • Spedali Riuniti di Pistoia

    Pistoia, Italy

  • ASP

    Potenza, Italy

  • Praia a Mare Hospital

    Praia a Mare, Italy

  • Operative Unit of Diabetologia - ASL 4

    Prato, Italy

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.